Anti-resorptives in the management of osteoporosis
- 31 October 2008
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 22 (5), 849-868
- https://doi.org/10.1016/j.beem.2008.07.004
Abstract
No abstract availableKeywords
This publication has 106 references indexed in Scilit:
- The Role of Bone Biopsy in Patients with Chronic Renal FailureClinical Journal of the American Society of Nephrology, 2008
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Estrogen and progestogen use in postmenopausal womenMenopause, 2008
- Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holidayOsteoporosis International, 2008
- Osteocytes, mechanosensing and Wnt signalingBone, 2008
- Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control studyBMJ, 2008
- Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort studyOsteoporosis International, 2006
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Osteoclast differentiation and activationNature, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002